News Novartis’ $100m bet on eczema drug fails as MOR106 development ends George Underwood atopic dermatitis, eczema, Galapagos, MorphoSys, Novatis 0 Comment Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in Share X Novartis’ $100m bet on eczema drug fails as MOR106 development ends https://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/
atopic dermatitis, eczema, Galapagos, MorphoSys, Novatis
0 Comment
